KCT0000961招募中未知
A Phase 2b, Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Second- or Third-line Treatment of Subjects with Unresectable Pleural or Peritoneal Malignant Mesothelioma
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
- MedImmune
- 入组人数
- 7
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional Study
入排标准
- 年龄范围
- 18(Year) 至 o Limit（—）
- 性别
- All
入选标准
- •1)Histologically and/or cytologically confirmed pleural or peritoneal malignant mesothelioma.
- •2)Disease not amenable to curative surgery;
- •3)Age 18 and over at the time of consent;
- •4)ECOG Performance status 0-1;
- •5)Progressed after Previous receipt of 1-2 prior systemic treatments for advanced disease that included a first-line pemetrexed (or anti-folate)-based regimen in combination with platinum agent;
- •6)Recovered from all toxicities associated with prior treatment;
- •7)Measurable disease;
- •8)Adequate bone marrow, hepatic, and renal function;
- •9)Negative screening test results for human immunodeficiency virus (HIV), hepatitis A, B and C;
- •10)Written informed consent and any locally required authorization (eg, HIPAA in the USA, EU Data Privacy Directive authorization in the EU) obtained from the subject/legal representative prior to performing any protocol-related procedures, including screening evaluations;
- •11)Females of childbearing potential who are sexually active with a nonsterilized male partner must use a highly effective method of contraception for 28 days prior to the first dose of investigational product, and must agree to continue using such precautions for 6 months after the final dose of investigational product;
- •12)Nonsterilized males who are sexually active with a female partner of childbearing potential must use a highly effective method of contraception from Day 1 through 90 post last dose.
排除标准
- •1) Received failed more than 2 prior systemic treatment regimens for advanced malignant mesothelioma;
- •2) Received any prior mAb against CTLA-4, programmed cell death 1 (PD1) or programmed cell death 1 ligand 1 (PD-L1);
- •3) History of chronic inflammatory or autoimmune disease ;
- •4) Active, untreated central nervous system (CNS) metastasis
- •5) Any serious uncontrolled medical disorder or active infection that would impair the subject’s ability to receive investigational product, such as conditions associated with frequent diarrhea;
- •6) History of other malignancy unless the subject has been disease-free for at least 3 years. Non-invasive cancer history (such as carcinoma in situ [CIS] that has been resected) is allowed;
- •7) Pregnant or breast feeding at time of consent;
- •8) Any condition that would prohibit the understanding or rendering of information and consent and compliance with the requirements of this protocol;
- •9) Active or history of diverticulitis. Note that diverticulosis is permitted;
- •10) Active or history of inflammatory bowel disease (eg, colitis, Crohn’s), irritable bowel disease, celiac disease or other serious gastrointestinal chronic conditions associated with diarrhea. Active or history of systemic lupus erythematosis or Wegener’s granulomatosis;
- •11) History of sarcoidosis syndrome;
- •12) Currently receiving systemic corticosteroids or other immunosuppressive medications or has a medical condition that requires the chronic use of corticosteroids. Note: inhaled and topical steroids are permitted;
- •13) Subjects should not be vaccinated with live attenuated vaccines within one month prior to starting tremelimumab treatment;
- •14) The last dose of prior chemotherapy or radiation therapy (with the exception of palliative radiotherapy) was received less than 2 weeks prior to randomization;
- •15) Any unresolved toxicity from previous anticancer therapy
- •16) Any condition that, in the opinion of the investigator, would interfere with evaluation of the investigational product or interpretation of subject safety or study results;
- •17) Concurrent enrollment in another clinical study or receipt of an investigational product within the last 4 weeks (participation in the survival follow-up period of a study is not an exclusion criterion);
- •18) Employees of the study site directly involved with the conduct of the study, or immediate family members of any such individuals;
- •19) Subjects with a history of hypersensitivity to compounds of similar biologic composition to tremelimumab or any constituent of the product.
研究者
相似试验
进行中（未招募）
1 期
Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Subjects with Unresectable Malignant MesotheliomaEUCTR2012-003524-21-GBMedImmune, LLC564
进行中（未招募）
1 期
Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Subjects with Unresectable Malignant MesotheliomaCTIS2024-511841-20-00AstraZeneca AB223
已完成
2 期
A Phase 2b, Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Second- or Third-line Treatment of Subjects with Unresectable Pleural or Peritoneal Malignant Mesotheliomainoperabel maligne mesothelioomPleural or Peritoneal MesotheliomaNL-OMON41613Medimmune LLC, subsidiary of AstraZeneca32
进行中（未招募）
不适用
Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Subjects with Unresectable Malignant MesotheliomaEUCTR2012-003524-21-NLMedImmune, LLC564
进行中（未招募）
1 期
Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Subjects with Unresectable Malignant Mesotheliomaunresectable pleural or peritoneal malignant mesotheliomaMedDRA version: 19.0Level: LLTClassification code 10034670Term: Peritoneal mesothelioma malignant localisedSystem Organ Class: 100000004864MedDRA version: 19.0Level: LLTClassification code 10035606Term: Pleural mesothelioma malignant localisedSystem Organ Class: 100000004864EUCTR2012-003524-21-DKMedImmune, LLC564